Prevention of hypertension in patients with pre-hypertension: protocol for the PREVER-prevention trial.

ABSTRACT:

Background

Blood pressure (BP) within pre-hypertensive levels confers higher cardiovascular risk and is an intermediate stage for full hypertension, which develops in an annual rate of 7 out of 100 individuals with 40 to 50 years of age. Non-drug interventions to prevent hypertension have had low effectiveness. In individuals with previous cardiovascular disease or diabetes, the use of BP-lowering agents reduces the incidence of major cardiovascular events. In the absence of higher baseline risk, the use of BP agents reduces the incidence of hypertension. The PREVER-prevention trial aims to investigate the efficacy, safety and feasibility of a population-based intervention to prevent the incidence of hypertension and the development of target-organ damage.

Methods

This is a

SUBMITTER: Fuchs FD 

PROVIDER: S-EPMC3059277 | biostudies-literature | 2011 Mar

REPOSITORIES: biostudies-literature